Introduction
The centrosome, a major microtubule organizing center of the animal cells, directs the formation of bipolar mitotic spindles as a spindle pole, which is essential for accurate chromosome segregation to daughter cells (for reviews, see Brinkley, 1985; Bornens, 1992; Lange and Gull, 1996) . Since each daughter cell inherits one centrosome, the centrosome must duplicate prior to the next mitosis, and do so only once. Thus, centrosome duplication must take place in coordination with other cell cycle events including DNA synthesis. In mammalian cells, the centriole, the core component of the centrosome, initiates duplication at the G1/S boundary (reviewed in Mazia, 1987; Vandre and Borisy, 1989; Tournier and Bornens, 1994) . Abrogation of the regulatory mechanism(s) that ensure the coordinated progression of centrosome duplication with other cell cycle events, and that limit centrosome duplication to only once per cell cycle, leads to abnormal ampli®cation of centrosomes (reviewed in Winey, 1996; Brinkley and Goepfert, 1998) . Recent studies have shown that centrosome hyperampli®cation is commonly observed, and is the major contributing factor for chromosome instability in human tumors (Pihan et al., 1998; Lingle et al., 1998; Weber et al., 1998; Carroll et al., 1999) . Moreover, loss or mutational inactivation of the p53 tumor suppressor protein, which occurs in human cancer at a high frequency (Hollstein et al., 1991; Levine et al., 1991) , strongly correlates with the occurrence of centrosome hyperampli®cation (Weber et al., 1998; Carroll et al., 1999) . Indeed, the centrosome duplication cycle is uncoupled from the DNA duplication cycle in cells derived from p53-null mice, leading to extensive centrosome hyperampli®ca-tion (Fukasawa et al., 1996 . Similar ®ndings have been made in cells transfected with dominantnegative mutant p53 (Wang et al., 1998) . These observations suggest that chromosome instability associated with loss or mutational inactivation of p53 results from the deregulation of the centrosome duplication cycle. p53 is involved in a variety of cellular processes primarily through its activity as a transcriptional factor (for reviews, see Gottlieb and Oren, 1996; Ko and Prives, 1996) . A majority of advanced human tumors have one mutant and one deleted p53 allele, and most of the mutated alleles have missense mutations clustered in the DNA binding domain, which abrogate the sequence-speci®c DNA binding activity of p53 and inhibit its transactivation function (Hollstein et al., 1991) . One of the major transactivation targets of p53 is p21
Waf1/Cip1 (Waf1) (El-Deiry et al., 1993) . Waf1 binds to and inhibits the G1/S cyclin-dependent kinase (CDK)-cyclin complexes, including CDK2/cyclin E (Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993) . CDKs, a family of serine/threonine kinases, control the onset of the major cell cycle events such as DNA synthesis and mitosis (reviewed in Nurse, 1994; Heichman and Roberts, 1994; Sherr, 1994) . The activity of CDKs are in part regulated by association with dierent cyclins, which are temporally expressed at speci®c cell cycle stages. For instance, cyclin E, which associates with CDK2, is expressed in late G1 (Ko et al., 1992; Dulic et al., 1992) , and the formation of active CDK2/cyclin E complexes is required for initiation of DNA replication (van den Heuvel et al., 1993; Ohtsubo and Roberts, 1993) . The activity of CDK2 is also regulated by a variety of CDK inhibitors, including Waf1 (recently reviewed in Sherr and Roberts, 1999) . Because of the recent ®ndings that the activation of CDK2/cyclin E (and cyclin A) is essential for the initiation of centrosome duplication (Hinchclie et al., 1999; Lacey et al., 1999; Meraldi et al., 1999) , it is not dicult to consider the possibility of Waf1 as a downstream eector of p53 in the regulation of centrosome duplication. Indeed, we have recently shown that the centrosome and DNA duplication cycles are also uncoupled in cells derived from Waf1-null mice (Mussman et al., 2000) , suggesting that Waf1 may be the eector of p53-associated regulation of centrosome duplication.
Although the implication of p53 in the regulation of centrosome duplication is strong, it remains to be examined whether abnormal ampli®cation of centrosomes is a direct or indirect consequence of mutational inactivation of p53. Loss or mutation of p53 is known to promote various types of genetic mutations (reviewed in Wahl et al., 1997) , hence the previous observations do not exclude the possibility that loss or mutational inactivation of p53 may indirectly induce centrosome hyperampli®cation through promoting mutation of genes whose products are directly involved in the regulation of the centrosome duplication cycle. If this is the case, reintroduction of p53 into p53 7/7 cells will not restore the normal centrosome duplication cycle. In this study, we tested this hypothesis. We found that the induced expression of a physiologically relevant level of p53 in embryonic ®broblasts derived from p53-null mice (p53 7/7 MEFs) almost completely restored the normal centrosome duplication cycle, demonstrating the direct involvement of p53 in the regulation of centrosome duplication. Moreover, induced expression of Waf1 in p53
MEFs resulted in partial restoration of the normal centrosome duplication cycle. Thus, p53 regulates centrosome duplication through waf1-dependent and -independent pathways.
Results

Generation of p53
7/7 MEF cell line with controlable expression of wt p53
To determine whether p53 controls the centrosome duplication cycle directly or indirectly, we tested whether re-introduction of wild-type p53 into p53
MEFs restores the normal centrosome duplication cycle. Since high level expression of p53 is expected to induce cell cycle arrest and/or apoptosis, we decided to use a`tetracycline (Tet)-on' inducible expression system, in which the gene expression is turned on iǹ Tet-On' cells by doxycycline (Dox; a Tet derivative). We generated a p53 7/7 MEF cell line that constitutively expresses a reverse Tet repressor (rtTA) [p53
We examined the centrosomes in the p53 7/7 (Tet) cell line using antibody against g-tubulin, a major component of centrosomes (reviewed in Joshi, 1994) ( Figure  1A ). For the controls, p53
+/+ and p53 7/7 MEFs were also immunostained. p53 +/+ MEFs showed an expected normal centrosome pro®le, in which *60% of cells contained one centrosome and *40% contained two centrosomes. Only 2 ± 3% of p53 +/+ cells contained abnormally ampli®ed centrosomes (n53). In contrast, p53 7/7 MEFs showed an abnormal centrosome pro®le with a decrease in the number of cells with one centrosome and an increase in the number of cells with two centrosomes, and *30% of cells showed centrosome hyperampli®cation, consistent with the previous observation (Fukasawa et al., 1996) . p53 7/7 (Tet) cells showed a centrosome pro®le similar to p53 7/7 MEFs, indicating that the expression of rtTA does not aect the centrosome behavior.
To verify whether the anti-g-tubulin antibodyreactive signals (dots) represented centrosomes with a pair of centrioles, cells were also immunostained for centrioles. Since a-tubulin is one of the major constituents of centrioles, immunostaining of a-tubulin allows visualization of a centriole pair within the centrosome. Cells were subjected to cold treatment and a brief extraction prior to ®xation (see Materials and methods), and co-immunostained with anti-g-tubulin polyclonal and anti-a-tubulin monoclonal antibodies ( Figure 1B ). Each dot detected by anti-g-tubulin antibody (panels a and e) was resolved to a pair of dots (representing a centriole pair) by anti-a-tubulin antibody at a higher magni®cation (panels b and f, panels I ± IV). Most of the hyperampli®ed centrosomes in p53 7/7 MEFs (not shown) and p53
(Tet) cells are intact, containing a pair of centrioles (panels III and IV). The centrosome pro®les determined by anti-atubulin antibody were similar to those determined by anti-g-tubulin antibody.
The p53
(Tet) cells were transfected with a pTREp53 (wild-type p53 under a Tet-inducible promoter) together with a plasmid encoding a hygromycinresistance gene as a selectable marker. As a control, a pTRE vector was transfected into the p53 (Tet) cells were immunostained for centrosomes using anti-g-tubulin antibody. The number of centrosome per cell was scored by¯uorescence microscopy. For each cell line, 4400 cells were examined. The results are shown as average+standard error determined from three separate experiments. One additional experiment was performed with coimmunostaining with anti-g-tubulin and anti-a-tubulin antibodies after cold-treatment and brief extraction for examination of a centriole pair within the centrosome (see below), which provided similar results. (B) Representative images of the centrosome (centrioles) immunostained with anti-g-tubulin and anti-a-tubulin antibodies. To determine whether each dot detected by anti-gtubulin antibody represents an intact centrosome with a centriole pair, cells were co-immunostained with anti-a-tubulin monoclonal (DM1A) (panels b and f) and anti-g-tubulin polyclonal (panels a and e) antibodies after cold-treatment and brief extraction, and detected by rhodamine-conjugated anti-mouse IgG and FITC-conjugated anti-rabbit IgG antibodies. Panels c and g show DAPI staining, and panels d and h show the overlay images. Panels a ± d, p53 +/+ MEFs; panels e ± h, p53
(Tet) cells. The arrow points to the centrosome, and the arrowhead in panels I ± IV points to a centriole pair. The images shown in panels I ± IV are 86magni®cation of the signals indicated in panels b and f. Scale bar, 20 mm became`unhealthy' and showed extensive cell death after Dox-treatment presumably due to the overexpression of transfected wild-type p53 upon induction (data not shown). Among the cell lines that continued to proliferate after induction, we selected one cell line [p53
(Tet)/p53 cells expressed low levels of p53 without induction (lane 2). Upon induction by Dox, however, the expression of p53 increased (lane 3) to the level similar to that in wildtype cells (lane 1).
We ®rst tested whether p53
(Tet)/p53 cells continued cell cycling during induction. After 4-day incubation with Dox, cells were analysed by¯ow cytometry ( Figure 3a ). p53 (Tet)/p53 can grow in the presence of physiologically relevant levels of wild-type p53. To further verify the cell cycling of these cells, we performed a BrdU-incorporation assay (2 hlabeling) after 4 days of Dox-treatment. We found that p53
(Tet)/p53 incorporated BrdU in the presence of Dox at a rate comparable to those of the uninduced or the control p53 7/7 (Tet)/Vec cells ( Figure 3b ).
Restoration of the normal centrosome duplication cycle by induced expression of wild-type p53
We examined the eect of induced expression of wildtype p53 in p53 7/7 MEFs on centrosome behavior. (Tet)/p53 cells expressed p53 at low levels without induction ( Figure 2 ). Cells were treated with Dox for 2 weeks. Since cells with 53 centrosomes continually undergo cell death largely due to defective mitoses (Fukasawa et al., 1996 , 2 week induction period was estimated to be sucient for the enrichment of the cells with the restored centrosome duplication cycle, allowing the assessment of changes in centrosome behavior resulting from induced expression of wildtype p53. Dox-treated cells were immunostained for the centrosomes, and the number of centrosomes per cell was scored (Figure 4a ). The control p53 7/7 (Tet)/Vec cells showed no change in a centrosome pro®le whether they were treated with Dox or not, indicating that Dox-treatment does not aect centrosome behavior. However, there was a substantial restoration of a centrosome pro®le in the Dox-treated p53
(Tet)/p53 cells, including an increase in the number of cells with one centrosome (from 27 ± 40%) and the decrease in the number of cells with n53 centrosomes (from 16 to 5%) when compared with the uninduced cells, (Tet)/p53 cells in the absence (7) and presence (+) of doxycycline (Dox) for 4 days. The extracts were subjected to immunoblot analysis using antip53 antibody (Pab421). As an additional control, we used the lysates from primary wild-type skin ®broblasts from an 8-weekold wild-type littermate of p53 7/7 mice. the reason of the use of skin ®broblasts as a control instead of MEFs is that p53 and Waf1, both of which have been implicated in cell cycle arrest and apoptosis, are examined in this experiment. Skin ®broblasts proliferate without any signs of crisis for 410 passages, while senescence and cell death can be detected in MEFs as early as passage 3. Thus, p53 or Waf1 may be up-regulated in those senesced or dead/dying MEFs, which may misrepresent the physiological levels of p53 and/or Waf1 of normal proliferating cells if p53 +/+ MEFs are used as a control. Indeed, when p53 levels were compared between wild-type MEFs and skin ®broblasts (passage 4), we detected slightly higher levels of p53 in MEFs than in skin ®broblasts (data not shown) (Tet)/p53 cells were treated with Dox for 4 days, and labeled with BrdU for 2 h (in the presence of Dox). BrdU-incorporation was scored by indirect immuno¯uorescence with anti-BrdU antibody (Boehringer Mannheim) demonstrating that re-introduction of physiological level of wild-type p53 re-established the normal centrosome pro®le.
To corroborate the above ®ndings, we examined whether the coordination of the centrosome and DNA duplication cycles was restored in p53 7/7 MEFs by induced expression of wild-type p53. The p53
(Tet)/ p53 and p53
(Tet)/Vec cells were ®rst treated with Dox for 2 weeks, followed by serum-starvation for 48 h in the presence of Dox. Cells were then serumstimulated in the presence of Dox. BrdU was included in the medium to monitor S phase entry. At every 4 h for a period of 16 h, BrdU-incorporation and the number of centrosomes per cell were scored ( Figure  4b ). Uncoupling of centrosome and DNA duplication was evident in p53 7/7 (Tet)/Vec cells irrespective of presence or absence of Dox. For instance, the rates of increase in the number of cells with 52 centrosomes during the initial 8 h of serum stimulation [denoted as R CEN (0 ± 8 h)] were 5.4%/h (7Dox) and 5.7%/h (+Dox). However, during this period, the rates of BrdU-incorporation [denoted as R BU (0 ± 8 h)] were 1.8%/h (7Dox) and 1.9%/h (+Dox). Thus, centrosomes initiate duplication much earlier than S phase entry in p53 (Tet)/p53 cells were Doxtreated, we observed a substantial decrease in the rate of centrosome duplication [R CEN (0 ± 8 h)=1.6%/h], which is similar to the rate of BrdU-incorporation. Thus, induced expression of wild-type p53 restored the coupling of the centrosome and DNA duplication cycles. These observations demonstrate that p53 is directly involved in the control mechanism underlying the coordinated initiation of centrosome and DNA duplication.
Partial restoration of the centrosome duplication cycle by induced expression of Waf1 in p53 7/7 MEFs
To test whether Waf1 is a downstream eector of p53 in the regulation of the centrosome duplication cycle, we (Tet)/p53 cells were serum-starved for 48 h, followed by serum-stimulation with the medium containing 20% FBS and BrdU (Dox-treatment was continued for the Dox-treated cells during serum-stimulation). At indicated time points, cells were ®xed and co-immunostained with anti-BrdU monoclonal and anti-g-tubulin polyclonal antibodies. The antigen-antibody complexes were detected by FITC-conjugated goat anti-mouse IgG (BrdU) and rhodamine-conjugated goat anti-rabbit IgG (centrosomes). The number of centrosomes per cell and BrdU incorporation was scored by¯uorescence microscopy. For each immunostaining, 4300 cells were examined examined the eects of induced expression of Waf1 in p53 7/7 MEFs. The p53
(Tet) cells were transfected with pTRE-waf1 (a plasmid containing waf1 under a Tet-inducible promoter) together with a plasmid encoding a hygromycin-resistance gene as a selectable marker. Hygromycin-resistant colonies were subcloned and examined for expression of Waf1 by immunoblot analysis ( Figure 5 ). We selected a cell line [p53 7/7 (Tet)/ Waf1], which expressed low levels of Waf1 under an uninduced state (lane 2). Upon induction by Dox, however, the expression of Waf1 increased (lane 3) to similar levels as in wild-type primary ®broblasts (lane 1).
We tested whether p53
(Tet)/Waf1 cells continued cell cycling during induction of Waf1. After 4-day incubation with Dox, cells were analysed by¯ow cytometry (Figure 6a ). p53 (Tet)/Waf1 cells can grow in the presence of physiologically relevant levels of Waf1. To verify the cell cycling of these cells, we performed a BrdU-incorporation assay (2 h-labeling) after 4 days of Dox-treatment as described in Figure 3 . We found that Dox treated p53 7/7 (Tet)/Waf1 cells incorporated BrdU (Figure 6b ) at a similar rate compared to the uninduced or the control p53 7/7 (Tet)/Vec cells (see Figure 3b) . We examined the eect of induced expression of Waf1 in the p53 (Tet)/ Waf1 cells in the absence of Dox showed a partial restoration in the centrosome pro®le, including an increase in the number of cells with one centrosome (*7%) and a decrease in the number of cells with n53 centrosomes (*11%) (Figure 7a ). This partial restoration under an uninduced state is likely due to the background expression of Waf1 (see Figure 5 , lane 2). p53
(Tet)/Waf1 cells were treated with Dox for 2 weeks, and immunostained for centrosomes as described for p53 7/7 (Tet)/p53 cells in Figure 4a . There was no signi®cant improvement in the centrosome pro®le after Dox-treatment when compared with the uninduced cells (Figure 7a ), suggesting that the background level of Waf1 in uninduced cells may have achieved the maximal restoration of the centrosomal defect associated with the decreased (or loss of) expression of Waf1 in p53 7/7 cells. We also tested the restoration of the coordination of centrosome and DNA duplication in p53 (Tet)/Waf1 cells in the absence (7) and presence (+) of doxycycline (Dox) for 4 days. The extracts were subjected to immunoblot analysis using anti-Waf1 polyclonal antibody (Ab-5, Calbiochem). As controls, the Dox-treated and untreated p53 7/7 (Tet)/Vec cells as well as wild-type mouse skin ®broblasts (see the legend to Figure 2) were included in the analysis (Tet)/p53 was no more than that in Dox-treated p53
(Tet)/Waf1, suggesting that Waf1 comprises one of the downstream eectors of p53, and p53 may exert additional, Waf1-independent regulation in the regulation of the centrosome duplication cycle.
Centrosome re-duplication capacity of Wt, Waf1 7/7 and p53 7/7 MEFs
To examine the role of Waf1 in the regulation of centrosome duplication further, we performed an assay that tests the centrosome re-duplication capacity of mammalian cells, which was initially developed by Balczon et al. (1995) . In this assay, cells are arrested at the G1/S boundary i.e. by aphidicolin or hydroxyureatreatment for 20 ± 60 h), and the number of centrosome per cell is analysed. In Chinese hamster ovary (CHO) cells arrested at the G1/S boundary, it has been shown that the centrosome continued to undergo re-duplication, resulting in multiple copies of centrosome (Balczon et al., 1995) . Wild-type (wt), Waf1 7/7 and p53 7/7 MEFs were treated with aphidicolin (Aph) for 36 h, and immunostained for centrosomes (Figure 9a) , the representa- (Tet)/Waf1 cells were subjected to immunostaining with anti-g-tubulin antibody, and the number of centrosome per cell was scored by¯uorescence microscopy. In parallel, Dox-treated (for 2 weeks) and untreated p53 7/7 (Tet)/Vec cells were analysed (not shown, see Figure 4a ). For each cell line, 4400 cells were examined. The data represent average+standard error determined by three separate experiments. One experiment was performed by co-immunostaining with anti-g-tubulin and anti-a-tubulin antibodies after cold-treatment and brief extraction, and we obtained similar results. (b) Partial restoration of coordination of the initiation of centrosome and DNA duplication by induced expression of Waf1. Dox-treated (for 2 weeks) and untreated p53 7/7 (Tet)/Waf1 cells were serum-starved for 48 h, followed by serum-stimulation with the medium containing 20% FBS and BrdU (Dox-treatment was continued for the Dox-treated cells during serum-stimulation). At indicated time points, cells were analysed for centrosomes and BrdU-incorporation as described in the legend to Figure 4b . In parallel, Dox-treated (for 2 weeks) and untreated p53 7/7 (Tet)/Vec cells were analysed as controls (not shown, see Figure 4b ). For each immunostaining, 4300 cells were examined Figure 9b ). In Waf1 7/7 MEFs, there was a substantial decrease in the number of cells with one centrosome (from 22 to 13%) and an increase in the number of cells with n53 centrosome (from 10 to 40%). In p53 7/7 MEFs, the changes were even more pronounced: the number of cells with one centrosome decreased from 18 to 3%, and the number of cells with n53 centrosomes increased from 31 ± 71%. In contrast, there was no signi®cant change in the centrosome pro®les in wt MEFs between pre-and post-Aph treatment. Thus, in wt MEFs, the centrosome does not undergo re-duplication when the cell cycle is halted by Aph-treatment, suggesting that p53 (and Waf1) is involved in suppression of centrosome re-duplication in cells arrested at the G1/S boundary.
To assess the integrity of the hyperampli®ed signals detected by anti-g-tubulin antibody in the Aph-treated
Waf1
7/7 and p53 7/7 MEFs, cells were co-immunostained with anti-g-tubulin and anti-a-tubulin antibodies after cold-treatment and brief extraction. Most (485%) of the centrosome in both Aph-treated Waf1 7/7 and p53 7/7 MEF were found to contain a pair of centrioles ( Figure 9C panels a ± d and I ± III). However, a minor population of centrosomes (10 ± 15%) were detected as a single dot by anti-a-tubulin antibody (panel I, indicated by an arrow), representing either centrosome fragmentation or splitting of a centriole pair.
Since activation of CDK2/cyclin E is required for initiation of centrosome duplication, we examined whether the p53-mediated checkpoint response (i.e. transactivation of waf1) is triggered during 36 h of Aph-treatment ( Figure 9E, top panel) . We detected an increase in Waf1 expression in wt MEFs, but not in p53
MEFs. Thus, Aph-treatment , and p53 7/7 MEFs were treated for 36 h with aphidicolin (Aph), and were immunostained with anti-g-tubulin antibody (B, panels a and b). Cells were also counterstained with DAPI (B, panels a' and b'). The number of centrosomes per cell was scored under ā uorescence microscope (A). The result shown is average+standard error determined from three separate experiments. For each cell lines, 4400 cells were examined. Scale bar in (B), 20 mm. In addition, one experiment was performed by co-immunostaining with anti-g-tubulin and anti-a-tubulin antibodies after cold-treatment and brief extraction, and we obtained similar results. 7/7 and p53 7/7 MEFs were subjected to immunoprecipitation with antibodies against cyclin E. The immunoprecipitates were subjected to an in vitro histone H1 kinase assay. The histone H1 phosphorylation activity was determined by phosphoimage analysis and shown in relative units. (E) The extracts prepared from Aph-treated (36 h) and untreated wt, Waf1 7/7 and p53 7/7 MEFs were subjected to immunoblot analyses using anti-Waf1 polyclonal, anti-cyclin E polyclonal, and anti-CDK2 monoclonal antibodies triggers the p53-dependent checkpoint pathway. The increased expression of Waf1 suggests that activity of CDK2/cyclin E may be suppressed in wt MEFs in extended Aph-treatment. To test this, CDK2/cyclin E complexes were immunoprecipitated with anti-cyclin E antibody from the Aph-treated cells at 0 and 36 h, and the immunoprecipitates were subjected to a histone H1 kinase assay ( Figure 9D ). Very low CDK2/cyclin E kinase activity was detected in wt MEFs after 36 h of Aph-treatment, while high levels of CDK2/cyclin E kinase activity were present in Waf1 7/7 and p53
cells. Since CDK2/cyclin E can be inactivated either by cyclin E degradation or increased expression of CDK inhibitors, we also probed the lysates with anti-cyclin E and anti-CDK2 antibodies ( Figure 9E ). All lysates contained comparable amounts of cyclin E (with *twofold increase after Aph-treatment) and CDK2, suggesting that loss of CDK2/cyclin E activity in Aphtreated wt MEFs is largely due to the p53-mediated upregulation of Waf1.
Re-introduction of p53 and Waf1 restores suppression of centrosome re-duplication in the Aph-arrested p53 7/7 cells
The Aph-treated p53 Taken together, Waf1 functions as an eector of p53-dependent checkpoint pathway(s), preventing premature initiation of centrosome duplication likely by inhibiting the untimely activation of CDK2/cyclin E. However, the dierence in the degree of centrosome reduplication between Waf1 7/7 and p53 7/7 cells suggests that suppression of re-duplication is only partially exerted by Waf1, and that p53 exerts additional Waf1-independent activities to suppress re-duplication.
Discussion
One of the important pro-carcinogenic properties resulting from mutational inactivation of p53 is destabilization of chromosomes. Studies of cultured cells as well as tumor tissues have shown that chromosome instability associated with inactivation of p53 is primarily attributed to the deregulated centrosome duplication cycle and the consequential centrosome hyperampli®cation. However, there had been no demonstration of direct induction of chromosome instability by loss or mutation of p53. Thus, there remained a possibility that p53 alteration might induce mutations in genes whose products are directly involved in the control of the centrosome duplication process. In this study, we tested whether p53 directly or indirectly controls the centrosome duplication cycle by re-introducing wild-type p53 into p53 7/7 cells: if the normal centrosome duplication cycle is restored by reintroduction of wild-type p53, p53 is directly involved in the regulation of centrosome duplication. We found that this was the case; induced expression of physiologically relevant levels of wild-type p53 in (Tet)/p53 cell lines were tested for the centrosome re-duplication capacity as described in Figure 8 . Cells were treated with Aph for 36 h in the presence of Dox, and were subjected to immunostaining with anti-g-tubulin antibody. For each cell line, 4400 cells were examined. The data represent average+standard error determined from three separate experiments. One experiment was performed by co-immunostaining with anti-g-tubulin and anti-a-tubulin antibodies after cold-treatment and brief extraction, and we obtained similar results
p53
7/7 cells almost completely restored the centrosome pro®le and the centrosome duplication cycle.
We have recently shown that constitutive activation of CDK2/cyclin E for forced expression of cyclin E results in uncoupling of the centrosome and DNA duplication cycles (Mussman et al., 2000) . In these cells, the centrosome initiate duplication in early G1 much before the onset of DNA synthesis. Unlike initiation of DNA synthesis which can only be triggered by CDK2/cyclin E after completion of a series of necessary events (Resnitzky et al., 1994; Ohtsubo et al., 1995) , initiation of centrosome duplication appears to primarily depend on the activation of CDK2/cyclin E (Mussman et al., 2000) . Thus, late G1-speci®c activation of CDK2/cyclin E serves as a checkpoint control for initiation of centrosome duplication as well as for coordination of the centrosome and DNA duplication cycles. This temporal activation of CDK2/cyclin E is under positive and negative regulations through expression of cyclin E and CDK inhibitors (Sherr and Roberts, 1999) . We have further shown that loss of Waf1 led to uncoupling of centrosome and DNA duplication as well as centrosome hyperampli®cation at similar levels with those induced by constitutive activation of CDK2/ cyclin E (Mussman et al., 2000) , suggesting that Waf1 monitors the timely initiation of centrosome duplication by suppressing premature activation of CDK2/ cyclin E. Involvement of Waf1 has also been suggested by others in dierent systems (Lacey et al., 1999; Matsumoto et al., 1999; Mantel et al., 1999) . However, we found that re-introduction of Waf1 into p53 7/7 cells only partially restored the centrosome pro®le and the centrosome duplication cycle. This is consistent with our previous ®ndings, in which more prominent aberration of the centrosome pro®le is observed in p53 7/7 MEFs than in Waf1 7/7 MEFs (Mussman et al., 2000) . Thus, even though Waf1 is an integral part of the p53-mediated checkpoint control that ensures the timely activation of CDK2/cyclin E (hence ensuring the timely initiation of centrosome duplication), Waf1 alone is not sucient for coordinating initiation of centrosome and DNA duplication. Since Waf1 is one of the major targets of p53's transactivation function, Waf1 may comprise one of the multiple eector pathways of p53 to coordinate the centrosome and DNA duplication cycles.
To study the regulation of the centrosome duplication process in cultured cells, the centrosome reduplication assay that examines the occurrence of centrosome re-duplication in CHO cells arrested at the G1/S boundary has been widely used (Balczon et al., 1995; Meraldi et al., 1999; Matsumoto et al., 1999) . In these cells, centrosome continuously re-duplicate in the absence of DNA duplication. To our surprise, similar results were only obtained in Waf1 7/7 and p53 7/7 cells, but not in wild-type cells. Thus, the p53-Waf1 pathway is critical for suppression of centrosome re-duplication in this assay system, limiting the duplication to once per cell cycle. In support, CHO cell lines have been found to have lost wild-type p53 function i.e. lack of G1 checkpoint in response to genotoxic stress), which is accompanied by a mutation in the DNA binding domain of p53 (Moro et al., 1995; Hu et al., 1999; Lee et al., 1997) . Disruption of the pre-programmed cell cycle progression is known to induce accumulation of p53 . Thus, one possibility is that an increase in the p53 protein level by extended Aph-treatment up-regulates Waf1 expression, resulting in inactivation of CDK2/cyclin E and inhibition of centrosome duplication. Indeed, we observed a clear increase in Waf1 levels in the Aphtreated wild-type MEFs, but not in the Aph-treated p53 7/7 or Waf1 7/7
MEFs. However, Waf1 again appears to play a partial role in the overall p53-mediated suppression of centrosome re-duplication. Induced expression of physiologically relevant levels of Waf1 only partially suppressed centrosome reduplication in p53 7/7 cells, while expression of physiologically relevant levels of p53 resulted in much stronger suppression of centrosome re-duplication. The level of Waf1 up-regulated by re-introduction of p53 is no more than the level of induced Waf1 in the Waf1-inducible cell line. Moreover, the degree of restoration resulting from the background level expression of Waf1 in the Waf1-inducible cells (2 ± 3-fold lower than the physiological level) did not improve signi®cantly when Waf1 was induced to a physiological level. These observations suggest that Waf1 has a limited capacity to restore the control of suppression of centrosome reduplication, and that Waf1 is not a sole eector of p53 in the suppression of centrosome re-duplication.
In summary, p53 regulates the coordinated initiation of centrosome and DNA duplication as well as suppression of centrosome re-duplication by multiple pathways in both Waf1-dependent and -independent manners. Indeed, it has recently been shown that GADD45 (another major target proteins of p53) is involved in the regulation of centrosome duplication (Hollander et al., 1999) . The functional role of GADD45 in centrosome duplication, however, remains to be elucidated. The involvement of Waf1 in the p53-mediated control of centrosome duplication may also account for centrosome hyperampli®cation resulting from mutations of BRCA1, the breast-cancer susceptibility gene, reported recently (Xu et al., 1999) . BRCA1 has been shown to up-regulate Waf1 in a p53-dependent (Ouchi et al., 1998) and p53-independent manner (Somasundaram et al., 1997) , suggesting that Waf1 may function as a downstream eector of BRCA1-mediated regulation of centrosome duplication. 
Materials and methods
Cells
, Waf1
7/7 and wt MEFs (generous gifts from Drs L Donehower and P Leder) were maintained in complete medium [Dulbecco Modi®ed Eagle Medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml)], in an atmosphere containing 10%
